Search results for: Real World Evidence (RWE)
Filter search results
Prevention pays off – so why aren’t we doing more of it?
5 June 2025
Share this: Simon Brassel Helen Hayes 2025 marks the midpoint of the World Immunisation Agenda, which, if fully implemented, will save 50 million lives over the next decade. Share this: We…
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
20 October 2025
…therapeutics, focused on disease modification or cure, rather than long-term treatment. In recognising the value of cell and gene therapies, and supporting this system-shift, the UK could realise these benefits…
Pharmaceuticals in Developing Countries
1 July 1983
The Office of Health Economics has recently widened its scope to take a special interest in the health care problems of the Poor World, with particular reference to. the role…
Health Economics: Prospects for the Future
1 July 1987
…areas and the World Health Organization, being considered by world experts. Other topics… The purpose of this book is to review the current state of health economics and look forward…
Arthritis
1 March 1992
Arthritis is a common and chronic disease with over 200 conditions included in this category. It affects every tenth inhabitant of the world according to the World Health Organisation (Novosti…
Born Too Soon
1 January 1993
…developed world. Although the impact on third World countries differs as the prevalent disease states, malnutrition and limited medical facilities reduce the chances of survival. Since preterm infants usually remain…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for Imperial College and the…
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…the US market. Despite H.R. 3’s unprecedented impact on the world’s largest pharmaceutical market, the CBO model projected that only 8 fewer new medicines (as measured by the number of…
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
…cost-effectiveness of vaccine programmes (Jit and Mibei, 2015). As described by the World Health Organisation (2019), this is because (i) there are often long delays between the vaccination event, the…